Teva extends global rebrand with tailored marketing messages for caregivers | Fierce Pharma
Fast-dissolving opioid dependence tablet wins EU recommendation - Drug Delivery Business
In opioid case, NY wants to probe Teva's control of Teva USA
District Court of Delaware rules that Actavis does not infringes with their Suboxone® and Subutex® generics
Patent Litigation Updates: CRISPR, Acorda's Ampyra, and Orexo Versus Teva | BioSpace
Orexo enters patent infringement litigation against Actavis
Teva Wins Patent Case Related to Orexo Opioid-Treatment Drug - Bloomberg
Teva Can Challenge Validity of Orexo Patent (Corrected)
Opioid Use Disorder Market Is Booming Worldwide 2023-2030 | Indivior PLC, Alkermes, Orexo AB, Titan Pharmaceuticals, Inc., Teva Pharmaceutical Industries Ltd. - Digital Journal
Orexo removes overhang on shares with key court win | Evaluate
IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF DELAWARE OREXO AB and OREXO US, INC., Plaintiffs, ACTAVIS ELIZABETH LLC,
Teva, denying 'any liability,' set aside $646M for opioid settlements. Here's why | Fierce Pharma
Annual Report
Orexo sues Actavis and Teva over narcotic dependency treatment
Full Year Report incl. Q4 2017
Orexo Ruling Hugely Significant | Potter Clarkson
Annual Report
Opioid Use Disorder Market Analysis to 2027 - Hikma Pharmaceuticals, Teva Pharmaceuticals, MediciNova, Orexo, Camurus, Omeros
Teva Can Challenge Validity of Orexo Patent (Corrected)
Suboxone sales down as opioid addiction drug market intensifies
Opioid Use Disorder Market Growth to register a CAGR of 8.7% to reach USD US$ 4,911.8 Million by 2028 | Indivior PLC, Alkermes, Orexo AB, Titan Pharmaceuticals, | Medgadget
Orexo misses out on millions after losing patent infringement suit against Actavis
